z-logo
Premium
Caspase inhibition reduces apoptotic death of cryopreserved porcine hepatocytes
Author(s) -
Yagi Toshikazu,
Hardin Joseph A.,
Valenzuela Yunuen M.,
Miyoshi Hideyuki,
Gores Gregory J.,
Nyberg Scott L.
Publication year - 2001
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1053/jhep.2001.24560
Subject(s) - cryopreservation , apoptosis , bioartificial liver device , caspase , programmed cell death , viability assay , hepatocyte , microbiology and biotechnology , biology , andrology , biochemistry , medicine , in vitro , embryo
Cryopreserved porcine hepatocytes are a ready source of metabolic function for use in a bioartificial liver (BAL). However, cryopreservation is associated with a loss of hepatocyte viability. The mechanism of cell death during cryopreservation is incompletely understood, but may involve apoptosis through caspase activation. This study evaluates the cytoprotective effect of a global caspase inhibitor, benzyloxycarbonyl‐Val‐Ala‐DL‐Asp‐fluoromethylketone (ZVAD‐fmk) during cryopreservation of porcine hepatocytes. Freshly isolated porcine hepatocytes (viability, 97.4% ± 0.9%) were cryopreserved in 60 μmol/L ZVAD‐fmk (+ZVAD group) or without ZVAD‐fmk (−ZVAD group) for 24 to 72 hours. Apoptotic and necrotic death were both observed after thawing and after 24 hours of culture. Caspase 3–like activity was significantly reduced by ZVAD‐fmk, and was associated with improved viability and reduced apoptotic death of porcine hepatocytes after cryopreservation. Mitochondrial membrane potential (MMP) was increased in cultures of porcine hepatocytes that were cryopreserved in ZVAD‐fmk. These results demonstrate the following: 1) Caspase 3–like protease activation and apoptosis occurs in porcine hepatocytes during cryopreservation; and 2) mitochondrial injury in this process is reduced by caspase inhibition.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here